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Abstract 
Anti-resorptive agent-related osteonecrosis of the jaw (ARONJ) is an intractable, although 
rarely occurs, complication in cancer patients with bone metastases and patients with 
osteoporosis who are treated with anti-resorptives including bisphosphonates and denosumab. 
Despite that more than 10 years have passed since the first cases of BRONJ was reported, 
our understanding of the epidemiology and pathophysiology of ARONJ still remains limited 
and data of ARONJ supported by evidence-based medicine are still poorly accumulated. 
However, diagnosis and staging of ARONJ, identification of risk factors, and development of 
preventive and therapeutic approaches have significantly advanced over the last a decade. 
The Position Paper 2017 is an updated version of the Position Paper 2010 of the Japanese 
Allied Committee on Osteonecrosis of the Jaw”, which is now consisted of six Japanese 
academic societies. The Position Paper 2017 describes new diagnostic definition for ARONJ 
according to AAOMS proposal, summarizes our current understandings of the 
pathophysiology of ARONJ based on literature search and suggests how physicians and 
dentists/oral surgeons should manage ARONJ, Further, the appropriateness of 
discontinuation of anti-resorptives (drug holiday) before, during and after invasive dental 
treatments is extensively discussed. More importantly, the manuscript also proposes for the 
first time the importance of interactive communication and co-operation between physicians 
and dentists/oral surgeons for successful treatment of ARONJ patients. It is expected that the 
Position Paper 2017 will be a guide to improve the management of ARONJ patients in Japan.   
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I. Background 
Bisphosphonates (BPs), which possess high chemical affinity to bone and specifically inhibit 
osteoclastic bone resorption, have been widely and safely used for the treatment of bone 
metastases and osteoporosis in which osteoclastic bone resorption is excessively increased. 
In 2003, Marx first reported many cases of BP-related osteonecrosis of the jaw (BRONJ) in 
cancer patients with bone metastasis and patients with osteoporosis who were treated with 
BPs [1]. BRONJ is a rare but an intractable disease. Since its pathophysiology remains 
unclear, physicians, dentists and oral surgeons have had difficulties in the management of 
BRONJ patients from early days until recently. However, our understanding of BRONJ is 
gradually and consistently advancing by analytical reviews of accumulating clinical and 
preclinical data on BRONJ over the last several years. In this context, it is particularly notable 
that recent clinical studies have showed that the occurrence of BRONJ is significantly 
decreased by blocking oral infection via extensive oral health control [2-4], suggesting that 
infection is a key step of the development of BRONJ. 
Denosumab, a human IgG2 monoclonal antibody against receptor activator of nuclear factor-
kappa B ligand (RANKL) [5], is a new therapeutic agent for osteoporosis and bone metastases 
with the half-life of approximately one month. Different from BPs that promote apoptosis in 
osteoclasts, denosumab inhibits osteoclastic bone resorption without causing apoptosis in 
osteoclasts. Further, denosumab does not deposit and persist in bones for a long period of 
time as do BPs, and thus the effects of denosumab are reversible. These pharmacological 
properties of denosumab initially led us to assume that ONJ unlikely occurs by treatment with 
denosumab. To our surprise, however, patients treated with denosumab also developed ONJ 
(DRONJ) clinically indistinguishable from BRONJ at almost the same incidence as BRONJ [6].  
Since both BP and denosumab, which show anti-bone resorption effects via different 
molecular mechanism of action, are associated with ONJ, anti-resorptive agent-related ONJ 
(ARONJ) [7] has been suggested as a comprehensive term representing both BRONJ and 
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DRONJ. Meanwhile, the American Association of Oral and Maxillofacial Surgeons (AAOMS) 
proposes the term, medication-related ONJ (MRONJ), based on the observations that anti-
angiogenic inhibitors and molecularly-targeted drugs such as tyrosine kinase inhibitors also 
are infrequently associated with ONJ or increase the incidence of BRONJ/DRONJ in cancer 
patients receiving BPs or denosumab, although global consensus has not been established 
yet [8]. In this position paper, the term ARONJ will be used according to the proposal of the 
International Task Force on Osteonecrosis of the Jaw [2] of which the Japanese Society for 
Bone and Mineral Research is a member. 
Since the first position paper on BRONJ was published by the Japanese Allied Committee on 
Osteonecrosis of the Jaw in 2010 [9], it has been passed 6 years, during which DRONJ has 
emerged, numerous and diverse ARONJ cases have been reported, and clinical and 
preclinical studies on ONJ have been accumulating, thereby increasing our understanding of 
ONJ and improving management of ONJ. The Position Paper 2017 is an updated and revised 
version of the Position Paper 2010 attempting to provide the latest clinical and basic 
information of ARONJ and propose a consensus for management of ARONJ in Japan.  
The paper is compiled by the Japanese Allied Committee on Osteonecrosis of the Jaw, which 
consists of diverse members of bone specialists, including physicians, orthopedic surgeons, 
rheumatologists, obstetricians, medical oncologists, oral surgeons, periodontologists, dental 
radiologists, oral pathologists, and cancer biologists. The Japanese Allied Committee on 
Osteonecrosis of the Jaw was organized through a collaboration of six academic societies: 
the Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese 
Society of Periodontology, Japanese Society of Oral and Maxillofacial Radiology, Japanese 
Society of Oral and Maxillofacial Surgeons, and the Japanese Society of Clinical Oral 
Pathology.  
 
II. Anti-resorptive agent-related osteonecrosis of the jaw (ARONJ) 
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1. Uniqueness of the jaw bone 
There are several unique anatomical and microbiological characteristics in the jaw bone that 
could be responsible for the specific occurrence of ARONJ in jaw bones. These characteristics 
are not found in bones in other parts of the body.  
1) The teeth erupt on the jaw bone breaking through the oral epithelium, allowing infectious 
factors, agents and microbes in the oral cavity directly invade into the jaw bone via the 
gap between epithelium and teeth or via root canal. 
2) The oral mucosa covering the jaw bone is thin and infection caused by mucosal injury 
spreads to the jaw bone beneath the mucosa. 
3) More than 800 types of resident bacteria (1011 to 1012/cm3) inhabit in dental plaques as 
sources of infection in the oral cavity. 
4) Inflammations due to tooth decay, pulpitis, periapical lesions, and periodontal diseases 
extend to the jaw bone. 
5) The jaw bone exposes to the oral cavity following invasive dental treatments including 
tooth extraction, leading to infection. 
Thus, the environments around jaw bone have a predisposition to readily get bacterial infection 
[10], which may be the reason why ARONJ occurs specifically in the jaw bone. 
 
2. Diagnosis of ARONJ 
AAOMS proposed additional diagnostic criteria for ONJ in 2014 and the Allied Committee 
agreed to adopt these new diagnostic criteria. Accordingly, ARONJ is definitely diagnosed 
when the following three conditions are met. 
1) Patients have history of treatment with BP or denosumab. 
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2) Patients have no history of radiation therapy to the jaw bone. Bone lesions of ARONJ 
must be differentiated from cancer metastases to the jaw bone by histological 
examinations. 
3) Exposure of alveolar bone in the oral cavity, jaw and/or face is continuously observed for 
longer than 8 weeks after first detection by medical or dental experts. Or the bone is 
palpable in the intra- or extra-oral fistula for longer than 8 weeks [8]. These criteria do not 
apply to a patient in Stage 0. 
 
3. Incidence of ARONJ 
The incidence of ARONJ varies depending on studies. There are no reliable epidemiologic 
data that are derived from evidence-based medicine. This position paper follows the data cited 
by the International Task Force on ONJ [2]. 
1) Patients with osteoporosis 
① BRONJ 
The incidence is 1.04 to 69 per 100,000 patients treated with oral administration per year, 
and 0 to 90 per 100,000 patients treated with intravenous administration per year. The 
incidence of ONJ in osteoporotic patients treated with oral/intravenous nitrogen-
containing BPs ranges from 0.001% to 0.01%, which is estimated to be almost the same 
or slightly higher than the incidence (0.001%) of ONJ in the general population. 
② DRONJ 
The incidence is 0 to 30.2 per 100,000 patients per year. 
2) Cancer patients 
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The incidence of ONJ in cancer patients is higher than that in patients with osteoporosis. 
Prospective studies of the incidence of ONJ have been conducted in cancer patients treated 
with zoledronic acid or denosumab. Of 5,723 patients with breast, prostate and other solid 
cancers and multiple myeloma, 52 patients (1.8%) treated with denosumab and 37 patients 
(1.3%) treated with zoledronic acid (i.e., 89 cancer patients in total) developed ONJ in 3 year 
follow-up [6, 11]. 
3) Incidence of ARONJ in Japan 
① BRONJ 
In nationwide surveys, The Japanese Society of Oral and Maxillofacial Surgeons found 
263 patients with BRONJ from the year of 2006 to 2008 [12] and 4,797 from the year of 
2011 to 2013 [13]. Approximately 40% of patients with BRONJ from 2006 to 2008 and 
half of those from 2011 to 2013 developed BRONJ following oral BP administration [12, 
13]. These results in Japan differ from the results obtained in other countries showing 
higher incidence of BRONJ in patients treated with intravenous BPs than oral BPs. The 
incidence of BRONJ in Japan is unknown, since data of the total number of patients 
treated with BPs are unavailable at the present time. 
② DRONJ 
A study conducted by a pharmaceutical company (Daiichi Sankyo) after denosumab was 
launched in the market reported that 120 cancer patients treated with denosumab from 
April 17, 2012 to July 31, 2015 developed DRONJ, and 58 of these patients had been 
treated with BPs before denosumab. 
Twenty patients with osteoporosis treated with denosumab from June 11, 2013 to 
December 31, 2015 developed DRONJ, and 15 of them had received BPs before 
denosumab.  
─ 9 ─  
4. Clinical manifestations and staging of ARONJ 
Clinical manifestations and staging of ARONJ are summarized in Table 1. Paresthesia in the 
chin, including the lower lip (Vincent’s symptom) of patients treated with BP is an early sign of 
ARONJ before alveolar bone exposure is detected. 
1) Stage 0 
The 2012 Position Paper (in Japanese) proposed that cases with ONJ-like clinical 
manifestations but no alveolar bone exposure can be diagnosed as Stage 0 ONJ. It is reported 
that Stage 0 ONJ accounts for 25-30% of ONJ, however, that half of Stage 0 cases heal 
without progression to Stage 1 [14]. Accordingly, the International Task Force on ONJ does 
not include Stage 0 in ONJ, concerning it may cause over-diagnosis [2, 15]. On the other hand, 
the AAOMS proposes that Stage 0 should be diagnosed and treated as a pre-ONJ [8]. This 
Position Paper includes Stage 0 in ONJ in agreement with the proposal of AAOMS from 
therapeutic points of view. However, it is strongly recommended that the diagnosis of Stage 0 
should be cautiously made to avoid over-diagnosis.    
2) Differences in clinical characteristics between BRONJ and DRONJ 
Clinical manifestations are indistinguishable between BRONJ and DRONJ at the present time. 
There is not sufficient information accumulated yet on imaging and histopathological 
characteristics of DRONJ that allows us to compare with those of BRONJ [16  
Incidence of DRONJ in cancer patients is reported to be less than 2% and equivalent to that 
of BRONJ [6, 11]. In contrast,  incidence of DRONJ in osteoporosis patients is unknown.  
3) Serum biochemical markers for bone turnover and ARONJ 
Value of serum biochemical markers of bone turnover is decreased by the treatment with BP 
and denosumab. Thus, it is expected that these markers are potentially useful for diagnosis, 
follow-up and assessment of therapeutic effects in patients with ARONJ [17]. However, most 
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clinical studies found no significant correlation between changes in these serum bone turnover 
markers and the occurrence and progression or healing of ARONJ [2]. Therefore, currently-
used bone turnover markers unlikely have diagnostic value for ARONJ. 
4) Imaging 
For patients under the treatment with low-dose anti-resorptives and with no evident clinical 
manifestations of ARONJ, intraoral and panoramic radiographs in conjunction with clinical 
manifestations are sufficient for diagnosis (Figure 1). Intraoral radiographs, which have high 
resolution, can reveal the site of infection in detail. 
For cancer patients being treated with high-dose anti-resorptives, it is recommended that 
intraoral radiographs of all existing teeth and panoramic radiographs should be undergone to 
identify potential sites of infection even if they have no signs of ONJ, since they potentially 
have increased risk for developing ONJ.  
For patients who are clinically suspected to have developed ONJ, computed tomography (CT) 
and dental cone-beam CT are helpful to detect early changes in trabecular and cortical bones 
of the jaws and assess the sequestra, fistula formation, periosteal responses and involved 
teeth. However, use of dental cone-beam CT is limited to localized lesions and supplemental 
to CT. CT must be combined with intraoral and panoramic radiographs. For cases in which 
differential diagnosis between ONJ and malignant tumors are required, use of CT and MRI, 
rather than dental cone-beam CT, is recommended. 
MRI, which allows assessment of changes in the bone marrow, may be useful for diagnostic 
evaluation of ONJ. For patients with ONJ who are under conservative and/or surgical 
treatments, the characteristics and extents of bone changes surrounding exposed bone can 
be assessed by CT and dental CT. MRI is useful for assessment of surrounding soft tissues, 
in addition to bones. Existing teeth that may be causes of infection can be detected by intraoral 
radiographs [18].  
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Recent studies have proposed that hybrid SPECT/CT may be useful for distinguishing ONJ 
lesions from unaffected healthy bone at the time of surgical interventions of ONJ [19, 20]. 
Simple PET using 18F-FDG and PET/CT may be also useful for assessment of ONJ lesions.  
At present, no specific differences in images between BRONJ and DRONJ have been 
described. 
5) Histopathological findings in ARONJ 
Although histopathological definition for diagnosis of ARONJ is yet to be established, several 
features of ARONJ are noted. The major histopathological finding of BRONJ is characterized 
by chronic osteomyelitis accompanied with osteonecrosis. In BRONJ lesions, there are 
relatively large osteoclasts detaching from the bone surfaces, which is similarly seen in bones 
treated with BPs [21] (Figure 2A). Trabecular bone exhibits mosaic-pattern lines of bone 
remodeling (Figure 2B), with increased thickness and decreased osteon density (osteon 
number/bone area). These histological views resemble those of bones in which osteoclastic 
bone resorption is inhibited by BP [22]. On the other hand, trabeculae bones with active 
inflammation demonstrate extensive osteoclastic bone resorption with resorption lacunae. Of 
note, Actinomyces colonies (resident bacteria in the oral cavity) are frequently present in 
contact with necrotic bones in ONJ lesions (Figure 2B, insert), raising the possibility that 
Actinomyces play a role in the pathogenesis of BRONJ [23]. 
A histopathological study on DRONJ published by a Japanese group showed that numbers of 
osteoclasts are decreased and immature osteoclasts with few nuclei are increased in DRONJ 
lesions presumably due to the action of denosumab [24]. However, whether these 
histopathological features are unique to DRONJ and distinct from those of BRONJ are 
currently unknown. 
 
5. Risk factors for ARONJ 
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Proposed risk factors for ARONJ are listed in Table 2. Of these risk factors, invasive dental 
treatments such as tooth extraction, dental implant and apical/periodontal surgery are 
definitely local risk factors for ARONJ. It should, however, be noted that the list is not made 
based on robust medical evidence but the summary of published reports the Allied Committee 
investigated. Here, risk factors that are newly listed are discussed.    
1) Dental implants and ARONJ 
Recent reports suggest that implants inserted before patients with cancer or osteoporosis are 
treated with BPs are unlikely associated with subsequent occurrence of BRONJ if oral health 
is appropriately managed [25, 26]. However, dental implantation performed during or after BP 
treatment is a potential risk factor for BRONJ.  
It is unknown whether dental implants are risk factors in patients receiving denosumab. Dental 
implant for cancer patients who are on the treatment with anti-resorptives is not recommended 
and alternative dental measures are recommended. On the other hand, dental implant in 
patients with osteoporosis may be performed in case physicians and dentists agree that dental 
implants are essential to improve systemic and oral health of patients. 
2) New therapeutic agents and ARONJ 
In Table 2, denosumab, ibandronate and anti-angiogenic agents and tyrosine kinase inhibitors 
are newly listed. Since the Position Paper 2010 was published, denosumab was launched in 
2012 in Japan and has been widely used in the treatment of bone metastases and 
osteoporosis with infrequent occurrence of DRONJ.  
Ibandronate was also launched as a new BP for the treatment of osteoporosis in Japan. A 
prospective study performed in Japan showed that there is no significant difference in the 
incidence of ONJ between osteoporotic patients treated with intravenous and oral ibandronate 
[27], suggesting that the route of administration does not influence the occurrence of BRONJ 
associated with ibandronate.  
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Anti-angiogenic agents and tyrosine kinase inhibitors, which are essentially administered as 
adjuvants in the treatment of cancer patients, have been shown to cause, although very rarely, 
by themselves or increase the incidence of ARONJ due to BP or denosumab [28]. 
 
6. Mechanism of ARONJ 
The mechanism responsible for ARONJ is not fully understood. In particular, it is a major 
question why the incidence of ARONJ is so low in osteoporotic patients, despite that millions 
of patients receive BP or denosumab. It is also unknown why ARONJ spontaneously develops 
in patients who are treated with anti-resorptives, but receive no invasive dental treatments. 
These issues can’t be explained only by the mechanisms currently proposed. Animal models 
in which ONJ is induced by administration of BP or RANKL inhibitors, followed by tooth 
extraction, have recently been developed in mice, rats, dogs and pigs [29-31]. It is expected 
that these animal models allow us to determine the pathophysiology and mechanism of 
ARONJ and develop new therapeutic interventions for ARONJ. Here, the mechanisms already 
described in the literature are summarized. Complex interactions of these mechanisms 
together with additional yet-unknown mechanisms are assumed to lead to the development 
and progression of ARONJ [29]. 
1) Inhibition of bone remodeling and excessive inhibition of osteoclast activity by anti-
resorptives 
2) Increased predisposition to oral bacterial infection due to BP administration 
3) BP suppression of remodeling and migration of oral epithelial cells 
4) Changes in immune surveillance by anti-resorptives 
5) Anti-angiogenic effects of BP 
6) Others 
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III. Dental treatments and discontinuation of anti-resorptives 
1. Dental treatments of patients who are to receive anti-resorptives 
Before starting administration of anti-resorptives, physicians need to explain to patients not 
only the benefits of anti-resorptives for bone metastases and osteoporosis but also risks of 
anti-resorptives for ONJ. It is wise to request patients to visit a dentist to control oral health to 
prevent the occurrence of ONJ. During dental treatments of these patients, interactive 
communication and close cooperation between physicians and dentists are essential. It is 
most appropriate that physicians inform dentists of the current status, clinical courses, 
therapeutic history and prognosis of the primary disease. Ideally, all dental treatments are 
expected to be completed 2 weeks before starting anti-resorptive treatment. However, in case 
anti-resorptive treatment can’t be delayed because of progression of bone metastases or high 
risk for fracture, administration of anti-resorptives in parallel with dental treatments may be 
acceptable. During treatment with anti-resorptives, physicians instruct patients to routinely visit 
a dentist to have oral examination. Dentists should inform physicians of the results of oral 
examinations and dental treatments as soon as they are done, so that there is no delay in anti-
resorptive administration by physicians. It is also helpful if physicians inquire patients the 
status of their oral cavity and teeth at their visit. 
2. Dental treatments of patients receiving anti-resorptives 
1) Discontinuation of BPs before starting dental treatments  
It is controversial whether discontinuation (drug holiday) of BPs for a certain period of time 
before starting invasive dental treatments is effective at preventing or decreasing the 
occurrence of BRONJ. The arguments are as follows: 
① There is little clinical evidence that short-term discontinuation of BPs helps prevent 
the occurrence of BRONJ resulting from invasive dental treatments. 
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② Based on the physiochemical properties of BPs that deposit and persist in the bone 
for a long period of time [5], it appears unlikely that short-term drug holiday of BPs 
prevents BRONJ.  
③ Survey conducted by the Japan Osteoporosis Society showed no changes in 
incidence of BRONJ in osteoporotic patients even if BPs or denosumab are 
discontinued before dental treatments [32, 33]. 
④ In osteoporotic patients who had BP drug holiday, there are exacerbations of 
osteoporosis including decreased bone mineral density and increased incidence of 
fractures [32-34]. 
⑤ Given extremely low incidence of BRONJ in osteoporosis, the benefits of BP for 
fracture prevention outweigh the risks for BRONJ [35]. 
⑥ Several recent studies reported that infection is a key event for BRONJ and that 
extensive infection control before invasive dental treatments decreases BRONJ [3]. 
Of particular note, this study also shows that BRONJ did not occur even in cancer 
patients who previously had BRONJ at other sites in the oral cavity if infection is 
properly controlled. These results suggest that infection control is most important 
for prevention of BRONJ. 
⑦ The American Dental Association estimated an incidence of ARONJ in patients 
with osteoporosis is, at the highest, up to 0.1% and suggests that the benefits of 
anti-resorptives for fracture prevention outweigh the risks for ARONJ. 
Discontinuation of anti-resorptives is unlikely to decrease the risk for ARONJ, but 
rather increase negative effects such as increased fractures [7]. 
These pieces of background collectively suggest that discontinuation  (drug holiday) of BP 
before starting invasive dental treatments is not logically supported.  
In contrast, however, the advisory board of the Food and Drug Administration (FDA) (http:// 
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www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafe
tyandRiskManagementAdvisoryCommittee/UCM270958.pdf), AAOMS [8, 17] and other 
groups [36, 37] described that the incidence of BRONJ increased in patients with osteoporosis 
who are treated with BPs for longer than 4 years in retrospective studies with small number of 
cases. From these results, AAOMS recommended that discontinuation of anti-resorptives for 
approximately 2 months before invasive dental treatments needs to be considered in case 
patients receive anti-resorptives for longer than 4 years and have low risk for fractures but 
potential high risk for BRONJ with a consultation with physicians [8]. The Japanese Society of 
Oral and Maxillofacial Surgeons, and other academic societies including the Korean Society 
for Bone and Mineral Research, the Korean Association of Oral and Maxillofacial Surgeons 
[38], and the International Association of Oral and Maxillofacial Surgeons (IAOMS) support 
the AAOMS proposal. Thus, no consensus has been reached yet regarding whether drug 
holiday of BP before invasive dental treatments is adequate and necessary for prevention of 
BRONJ. Prospective clinical studies should be performed under the cooperation of allied 
teams of physicians, dentists and oral surgeons, hopefully at international levels to include as 
many as BRONJ cases, to address this important issue. Whatever the results of the studies, 
however, it is most important that invasive dental treatments for patients who are receiving 
anti-resorptives are conducted with careful and meticulous surgical techniques under 
elaborative planning in conjunction with extensive control of oral infection. 
2) Suggested dental treatments of patients with cancer and osteoporosis who are receiving 
BPs 
There are many review articles that propose the practical approaches to prevent the 
occurrence of BRONJ in patients who are receiving BPs during dental treatments [2-4, 7, 8]. 
The Position Paper 2017 proposes the followings as an example. Dental experts will need to 
educate patients on the importance of daily oral sanitation including how to clean the oral 
cavity after each meal and rinse their mouth with antibacterial mouthwash. In parallel, dentists 
make efforts to eliminate causes of infection such as dental plaque, calculus, tooth decays, 
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remaining roots, periodontitis, apical lesions, ill-fitting dentures, crowns and inlays as much as 
possible. Subsequently, dentists can begin conservative dental treatments without 
discontinuation of BPs. In case, however, invasive dental treatments such as removal of teeth 
responsible for BRONJ are inevitable, antibacterial agents are administered to patients in 
advance and invasive dental treatments should be restricted to as minimum extent and area 
as possible without discontinuation of BPs. At the end of the invasive treatments, remaining 
sharp edges of alveolar bones should be smoothened, and surgical wounds are to be closed 
primarily with mucoperiosteal flap lined by the periosteum. 
3) Suggested dental treatment of patients with cancer and osteoporosis who are receiving 
denosumab 
Denosumab has significantly superior benefits for cancer patients with bone metastases than 
does zoledronic acid [11]. The incidence of DRONJ was found to be equivalent to that of 
BRONJ in cancer patients [6]. Occurrence of DRONJ in patients with osteoporosis under 
treatment with denosumab is also reported in Japan, although the incidence is extremely low 
[39]. Similar to patients treated with BPs, dentists conduct conservative dental treatments 
without drug holiday. Invasive dental treatments, if inevitable, can be conducted without drug 
holiday following appropriate infection control. A recent case report showed uneventful healing 
of tooth extraction sockets by closing the sockets with oral mucosa to prevent secondary 
infection in patients under denosumab [40]. Interestingly, another case report from Japan 
described that DRONJ in colon cancer patients with bone metastases healed after 
discontinuation of denosumab [41], suggesting that the actions of denosumab are reversible. 
Given that denosumab is administered to osteoporotic patients once every 6 months and the 
half-life of denosumab is approximately one month, there is room to consider the timing and 
plan of dental treatments between the 6 month intervals. 
Of note, intriguing experimental results in a mouse model in which administration of 
osteoprotegerin (OPG)-Fc or zoledronic acid caused ONJ were recently reported [31]. In this 
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model, ONJ was spontaneously healed by discontinuation of OPG-Fc, while ONJ was not 
healed by discontinuation of zoledronic acid. Since OPG-Fc has RANKL inhibitory action 
similar to denosumab, these findings are consistent with the notion that the effects of 
denosumab are reversible. 
4) Discontinuation of anti-resorptives after invasive dental treatments 
Anti-resorptives may interfere with the healing of surgical wounds, especially epithelialization 
of wounds [29]. In this case, it may be required to temporarily discontinue the administration 
of anti-resorptives or change to alternative therapeutic drugs unassociated with ONJ until 
surgical wounds completely heal. Continuation or discontinuation of anti-resorptives needs to 
be decided depends on fracture risk evaluated by the “Guidelines on the prevention and 
treatment of osteoporosis 2015” [42] and the status of the healing of surgical wounds in the 
oral cavity under agreement between physicians and dentists. 
5) Timing of resuming the administration of anti-resorptives  
Timing of re-starting administration of anti-resorptives after drug holiday is dependent on the 
balance between healing of surgical wounds and control of the primary disease. If fracture risk 
or bone metastasis is well-controlled, it is recommended that the treatment with anti-
resorptives is resumed approximately two months after invasive dental treatments, when the 
alveolar bones damaged are expected to heal. However, if fracture risk is high or bone 
metastasis progresses during drug holiday and re-administration of anti-resorptives is urgent, 
and if there are no signs of infection around surgical wounds, two weeks after the invasive 
dental treatments, when epithelialization of the surgical site is almost complete, may be the 
earliest timing. Dentists are expected to immediately inform physicians of healing of surgical 
wounds, so that administration of anti-resorptives is resumed without delay. 
3. Dental treatment of pediatric patients treated with BPs for osteogenesis imperfecta (OI) 
Intravenous injection of pamidronate is most commonly used for treatment of pediatric patients 
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with OI. There are no reports of BRONJ in these patients following dental treatments including 
tooth extraction [43, 44]. Denosumab has also beneficial effects on OI [45]. It is unknown 
whether these pediatric OI patients developed DRONJ following invasive dental treatments. 
 
IV. Management of ARONJ 
Management of BRONJ by dentists and oral surgeons has markedly improved. In contrast, 
there is still much less information on the management of DRONJ. Since inhibitory effects of 
denosumab are transient and reversible, it seems that prognosis of DRONJ is less serious 
than BRONJ. However, since the differences in the pathophysiological characteristics 
between DRONJ and BRONJ are currently unclear, it is recommended that BRONJ and 
DRONJ are essentially treated in similar manners. 
The therapeutic recommendations described below are a summary of case studies and 
opinions of experts previously published and are not validated by evidence-based medicine. 
1. Goal of treatment of ARONJ 
Treatment of ARONJ should be performed along with the following three principles: 
1) Blockade of ONJ extension 
2) Maintenance of QOL of patients by relieving symptoms including pain, pus discharge and 
paresthesia and by control of infection 
3) Education and routine follow-up for oral health care in patients by dental experts. 
2. Treatment of ARONJ  
1) Choice of conservative or surgical treatments 
Treatment of ARONJ varies with the stage of the disease. However, regardless of stages, it is 
required to treat dental and periodontal diseases, maintain and improve oral health with 
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antibacterial mouthwash, and systemically administer antibacterial agents. Importantly, 
isolated sequestra must be eliminated to promote healing of soft tissues and prevent further 
extension of ONJ. 
Therapeutic strategies according to ARONJ stage are summarized in Table 3. Until several 
years ago the first-line treatment for ARONJ was conservative approaches and surgical 
therapies were performed only when ONJ advancement and prevailing of infection could not 
be prevented by conservative ways. However, many recent clinical case studies showed that 
Stage 2 and Stage 3 ARONJ are cured better by surgical than conservative therapies [46], 
leading to a trend to prefer surgical approaches to conservative ones [3, 4, 8, 13]. To make 
surgical approaches successful, complete elimination of ARONJ lesions and closure of 
surgical wounds with systemic administration of antibacterial agents are critical. If patients 
have a history of malignant tumor, all necrotic bones removed will need to be examined by 
histopathology to exclude that excised ARONJ lesions are tumor metastases to the jaws. 
Isolated sequestra should be completely removed without exposing healthy bones 
surrounding ARONJ lesions, regardless of disease stage. Further, since tooth extraction per 
se is unlikely to exacerbate existing ARONJ lesions, removal of affected teeth in exposed 
necrotic bones is recommended. For Stage 1 ARONJ, however, conservative approaches are 
still recommended [47]. Notably, however, the same authors recommended surgical therapies 
if ARONJ advances to Stage 2 or 3 [48]. Thus, improvement of surgical techniques and control 
of infection are requisites for better and successful management of ARONJ.  
2) Administration of antibacterial agents 
There are no evidence-based recommendations for what kinds of antibacterial agents are 
chosen and how long these agents are administered for ARONJ treatment. The survey 
conducted by the Japanese Society of Oral and Maxillofacial Surgeons showed that various 
classes of antibacterial agents were given intravenously, orally or mixed for a varying period 
of time. Of interest, a study from a Japanese group reported that 2- to 10-week administration 
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of sitafloxacin resolved or cured some cases of Stage 2 and Stage 3 BRONJ [49]. However, 
long-term administration of antibacterial agents may not be recommended considering 
acquisition of drug-resistance in the future use of antibacterial agents. 
3) Treatment with parathyroid hormone (Teriparatide) 
Systemic administration of low-doses of recombinant parathyroid hormone (teriparatide) is 
shown to resolve ONJ symptoms and promote cure [50]. Studies in Japan have also shown 
that bone regeneration and healing in ONJ lesions are improved by teriparatide [51, 52]. 
However, these results are all derived from case reports but not prospective randomized 
controlled studies and thus do not provide yet robust medical evidence to endorse the use of 
teriparatide for ARONJ treatment. It should also be noted that administration of teriparatide is 
a contra-indication for patients with metastatic bone tumor and there is also strict restriction 
for its total dose and period of administration. Thus, the advantages and benefits of teriparatide 
administration in the treatment of ARONJ still need to be validated.  
4) Other treatments 
Low-intensityl laser therapy, hyperbaric oxygen therapy and local administration of platelet-
derived growth factor (PDGF) have also been attempted, but their efficacies are uncertain at 
present [2, 4]. 
3. Administration of anti-resorptives to patients under ARONJ treatments 
It is unknown whether discontinuation or continuation of anti-resorptives is adequate in 
patients who suffer from ARONJ. Discontinuation of anti-resorptives in cancer patients with 
progressive bone metastases seems inadequate. On the other hand, for patients with 
osteoporosis, excluding those with high fracture risk, discontinuation of anti-resorptives may 
be recommended until the treatments of ARONJ are completed. In support of validity of drug 
holiday during ARONJ treatments, a study reported that resolution of ARONJ is faster by six 
months in patients who had drug holiday than those who continued to receive anti-resorptives 
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after surgical treatments for ARONJ [53]. 
4. Importance of the cooperation between physicians and dentists in ARONJ treatment 
Survey results of the Japan Osteoporosis Society indicated that dentists frequently requested 
discontinuation of anti-osteoporotic agents unrelated with ARONJ and nearly 30% of these 
agents were drugs other than BPs or denosumab [32, 33]. Therefore, dentists should re-
recognize that not all anti-osteoporotic agents are associated with ARONJ. On the other hand, 
the same survey showed that 62% of physicians have not requested oral health care to 
dentists and 72% have not consulted with dentists before starting administration of anti-
resorptives [33]. These results suggest a lack of communications and interactions between 
physicians and dentists in the treatments of patients with ARONJ, creating the circumstances 
in which incidence of ARONJ is still increasing in Japan. ARONJ is a disease that possesses 
both medical and dental aspects that require harmonious and systematic managements by 
both physicians and dentists. The Allied Committee strongly recommends that the team 
consisting of medical and dental experts is organized for establishment of preventive and 
therapeutic approaches for ARONJ. 
 
V. Future perspectives 
Despite that more than 10 years have passed since the first report of BRONJ was published, 
our understanding of the epidemiology and pathophysiology of ARONJ still remains limited. It 
is almost certain that new anti-resorptive agents with distinct molecular mechanisms of actions 
and pharmacokinetics from those of currently-available anti-resorptives will emerge and be 
used for treatment of osteoporosis and bone metastases in the near future, inducing the 
occurrence of ONJ of different clinical characteristics from BRONJ and DRONJ. To properly 
control these future situations, identification of risk factors and understanding of 
pathophysiological mechanisms of ARONJ are mandatory. The most enigmatic issue at 
present is why the incidence of ARONJ in patients with osteoporosis is only one per 10,000 to 
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100,000 people per year. If the risk factors listed in Table 2 are associated with the occurrence 
of ARONJ, the incidence of ARONJ are most likely much higher, suggesting that yet-unknown 
mechanisms or risk factors contribute to ARONJ. Further, the mechanism of ARONJ that 
spontaneously occurs in patients receiving anti-resorptives without invasive dental treatments 
also needs to be uncovered. 
Pre-clinical animal models are an essential tool to determine the mechanism of diseases to 
enable to design mechanism-based therapeutic interventions. Several animal models of 
ARONJ have been developed over the last several years and have significantly advanced our 
understanding of the pathophysiology of ARONJ [29-31]. However, these animal models only 
partially represent the pathologic conditions of human ARONJ and clinical relevance of these 
animal models is yet far satisfactory. Thus, animal models of ARONJ that more closely 
resemble human ARONJ need to be established to further advance ARONJ research and 
treatments. It is also noted that there are many hurdles to overcome to extrapolate the results 
obtained in animal models to patients. 
There are also many challenging issues to be addressed. At cellular levels, our understandings 
of the effects of anti-resorptives on the differentiation, proliferation and motility of oral epithelial 
cells that play a critical role in closure of tooth extraction sockets to protect alveolar bone from 
exposure to oral cavity are poor. Further, responses of immune cells and hematopoietic stem 
cells in bone marrow that directly or indirectly contribute to bone remodeling to anti-resorptives 
are also still unclear. 
Clinical issues to be addressed include, 1) significance and effects of drug holiday of anti-
resorptives with respect to ARONJ prevention, 2) choice and regimen of antibacterial agents 
for ARONJ prevention, 3) drug resistance induced as a consequence of long-term use of 
antibacterial agents, 4) development of imaging techniques for better detection of margins of 
ARONJ lesions to facilitate surgical treatments, 5) definitive criteria for making decisions for 
conservative, surgical or combined approaches for ARONJ treatment according to the stage 
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of ARONJ, 6) evidence-based effectiveness of medicinal therapies for ARONJ including 
teriparatide and other bone-modifying agents, and 7) validation of therapeutic value of 
hyperbaric oxygen and low-intensity laser. 
Recently, necrosis of the external auditory canal associated with the treatment with BPs have 
been reported, although cases are extremely few [54], The Pharmaceuticals and Medical 
Devices Agency (PMDA) of Japan lists it as a serious adverse effect and alerts users to those 
adverse effects. 
Patients should not receive any disadvantages during the treatments of osteoporosis, bone 
metastases and ARONJ due to a lack of communications between physicians and dentists 
[55]. One reason for increasing occurrence of ARONJ in Japan could be attributable to poor 
interest and understanding of dental treatments by physicians. In the meantime, dentists must 
recognize that the incidence for ARONJ is extremely low and anti-resorptives are safe and 
beneficial drugs for fracture prevention and suppression of bone metastases. Dentists are 
expected to correctly and accurately know the mechanism of action and indication of anti-
resorptives and should not turn down dental treatments of ARONJ patients by unnecessarily 
and non-scientifically concerning ARONJ occurrence. It is inappropriate to request physicians 
for modification of therapeutic strategies of osteoporosis during dental treatments. The Allied 
Committee proposes to establish intimate cooperative environments that allow physicians and 
dentists to share the epidemiologic, pathophysiologic, diagnostic and therapeutic information 
of patients to provide the best treatments for patients with ARONJ. 
 
VI. Conclusion 
ARONJ, although rarely occurs, is an intractable complication in cancer patients with bone 
metastases and patients with osteoporosis who are treated with anti-resorptives. Data of 
ARONJ supported by evidence-based medicine are still poorly accumulated. However, 
diagnosis and staging of ARONJ, identification of risk factors, and development of preventive 
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and therapeutic approaches have significantly advanced over the last a decade. In particular, 
the reports showing that extensive infection control in the oral cavity before invasive dental 
treatments decreases or prevents occurrence of ARONJ are encouraging for physicians who 
prescribe anti-resorptives and dentists/oral surgeons who treat ARONJ. For successful 
treatment of each individual case of ARONJ, the best therapeutic options should be chosen 
with informed consent under the agreement of a collaborative team of physicians, dentists, 
oral surgeons and co-medical and -dental staffs who share consolidated information on the 
patient. 
Finally, it should be noted that this Position Paper 2017 describes summaries of bodies of 
current information on ARONJ available in literature but does not provide proposals supported 
by evidence-based medicine.  
  
─ 26 ─  
References 
 
1. Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular 
necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115-1117  
2. Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, Reid IR, 
Ruggiero SL, Taguchi A, Tetradis S, Watts NB, Brandi ML, Peters E, Guise T, Eastell R, 
Cheung AM, Morin SN, Masri B, Cooper C, Morgan SL, Obermayer-Pietsch B, Langdahl 
BL, Al Dabagh R, Davison KS, Kendler DL, Sándor GK, Josse RG, Bhandari M, El 
Rabbany M, Pierroz DD, Sulimani R, Saunders DP, Brown JP, Compston J; International 
Task Force on Osteonecrosis of the Jaw (2015) Diagnosis and management of 
osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner 
Res 30:3-23  
3. Otto S, Tröltzsch M, Jambrovic V, Panya S, Probst F, Ristow O, Ehrenfeld M, Pautke C 
(2015) Tooth extraction in patients receiving oral or intravenous bisphosphonate 
administration: A trigger for BRONJ development? J Craniomaxillofac Surg 43:847-854  
4. Campisi G, Fedele S, Fusco V, Pizzo G, Di Fede O, Bedogni A (2014) Epidemiology, 
clinical manifestations, risk reduction and treatment strategies of jaw osteonecrosis in 
cancer patients exposed to antiresorptive agents. Future Oncol 10:257-275  
5. Baron R, Ferrari S, Russell RG (2011) Denosumab and bisphosphonates: different 
mechanisms of action and effects. Bone 48:677-692  
6. Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, Diel IJ, Takahashi 
S, Shore N, Henry DH, Barrios CH, Facon T, Senecal F, Fizazi K, Zhou L, Daniels A, 
Carrière P, Dansey R (2012) Incidence, risk factors, and outcomes of osteonecrosis of the 
jaw: integrated analysis from three blinded active-controlled phase III trials in cancer 
patients with bone metastases. Ann Oncol 23:1341-1347  
7. Hellstein JW, Adler RA, Edwards B, Jacobsen PL, Kalmar JR, Koka S, Migliorati CA, Ristic 
H; American Dental Association Council on Scientific Affairs Expert Panel on 
Antiresorptive Agents (2011) Managing the care of patients receiving antiresorptive 
─ 27 ─  
therapy for prevention and treatment of osteoporosis: executive summary of 
recommendations from the American Dental Association Council on Scientific Affairs. J 
Am Dent Assoc 142:1243-1251  
8. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O'Ryan F 
(2014) American Association of Oral and Maxillofacial Surgeons Position Paper on 
Medication-Related Osteonecrosis of the Jaw-2014 Update. J Oral Maxillofac Surg 
72:1938-1956  
9. Yoneda T, Hagino H, Sugimoto T, Ota H, Takahashi S, Soen S, Taguchi A, Toyosawa S, 
Nagata T, Urade M (2010) Bisphosphonate-related osteonecrosis of the jaw: Position 
paper from the allied task force committee of Japanese Society for Bone and Mineral 
Research, Osteoporosis Society Japan, Japanese Society of Periodontology, Japanese 
Society for Oral and Maxillofacial Radiology and Japanese Society of Oral and 
Maxillofacial Surgeons. J Bone Miner Metab 28: 365-383  
10. Hinson AM, Smith CW, Siegel ER, Stack BC Jr (2014) Is bisphosphonate-related 
osteonecrosis of the jaw an infection? A histological and microbiological ten-year summary. 
Int J Dent 2014:452737  
11. Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena 
S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad 
F, Ke C, Braun A, Jun S (2012) Superiority of denosumab to zoledronic acid for prevention 
of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. 
Eur J Cancer 48:3082-3092  
12. Urade M, Tanaka N, Furusawa K, Shimada J, Shibata T, Kirita T, Yamamoto T, Ikebe T, 
Kitagawa Y, Fukuta J (2011) Nationwide survey for bisphosphonate-related osteonecrosis 
of the jaws in Japan. J Oral Maxillofac Surg 69:e364-e371  
13. Japanese Society of Oral and Maxillofacial Surgeons (2015) Nationwide survey for 
BRONJ management. (In Japanese) 
14. Fedele S, Porter SR, D'Aiuto F, Aljohani S, Vescovi P, Manfredi M, Arduino PG, Broccoletti 
R, Musciotto A, Di Fede O, Lazarovici TS, Campisi G, Yarom N (2010) Nonexposed variant 
─ 28 ─  
of bisphosphonate-associated osteonecrosis of the jaw: a case series. Am J Med 
123:1060-1064  
15. Khan A, Morrison A, Cheung A, Hashem W, Compston J (2016) Osteonecrosis of the Jaw 
(ONJ) diagnosis and management in 2015. Osteoporos Int 27:853-859,  
16. Boquete-Castro A, Gómez-Moreno G, Calvo-Guirado JL, Aguilar-Salvatierra A, Delgado-
Ruiz RA (2016) Denosumab and osteonecrosis of the jaw. A systematic analysis of events 
reported in clinical trials. Clin Oral Implants Res 27:367-375  
17. Marx RE, Cillo JE Jr, Ulloa JJ (2007) Oral bisphosphonate-induced osteonecrosis: risk 
factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral 
Maxillofac Surg 65:2397-2410  
18. Taguchi A, Akiyama H, Koseki T, Shimizutani K (2013) Recognition of bisphosphonate-
related osteonecrosis of the jaw among oral and maxillofacial radiologists: results from a 
questionnaire-based survey in Japan. Oral Radiol 29: 98-104  
19. Miyashita H, Shiba H, Kawana H, Nakahara T (2015) Clinical utility of three-dimensional 
SPECT/CT imaging as a guide for the resection of medication-related osteonecrosis of 
the jaw. Int J Oral Maxillofac Surg 44:1106-1109  
20. Assaf AT, Zrnc TA, Remus CC, Adam G, Zustin J, Heiland M, Friedrich RE, Derlin T (2015) 
Intraindividual comparison of preoperative (99m)Tc-MDP SPECT/CT and intraoperative 
and histopathological findings in patients with bisphosphonate- or denosumab-related 
osteonecrosis of the jaw. J Craniomaxillofac Surg 43:1461-1469                
21. Weinstein RS, Roberson PK, Manolagas SC (2009) Giant osteoclast formation and long-
term oral bisphosphonate therapy. N Engl J Med 360:53-62  
22. Favia G, Pilolli GP, Maiorano E (2009) Histologic and histomorphometric features of 
bisphosphonate-related osteonecrosis of the jaws: an analysis of 31 cases with confocal 
laser scanning microscopy. Bone 45:406-413  
23. De Ceulaer J, Tacconelli E, Vandecasteele SJ (2014) Actinomyces osteomyelitis in 
bisphosphonate-related osteonecrosis of the jaw (BRONJ): the missing link? Eur J Clin 
Microbiol Infect Dis 33:1873-1880  
─ 29 ─  
24. Matsushita Y, Hayashida S, Morishita K, Sakamoto H, Naruse T, Sakamoto Y, Yamada SI, 
Yanamoto S, Fujita S, Ikeda T, Umeda M (2016) Denosumab-associated osteonecrosis of 
the jaw affects osteoclast formation and differentiation: Pathological features of two cases. 
Mol Clin Oncol 4:191-194  
25. Holzinger D, Seemann R, Matoni N, Ewers R, Millesi W, Wutzl A (2014) Effect of dental 
implants on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 
72:1937, e1-e8  
26. Matsuo A, Hamada H, Takahashi H, Okamoto A, Kaise H, Chikazu D (2016) Evaluation of 
dental implants as a risk factor for the development of bisphosphonate-related 
osteonecrosis of the jaw in breast cancer patients. Odontology 104:363-371  
27. Nakamura T, Ito M, Hashimoto J, Shinomiya K, Asao Y, Katsumata K, Hagino H, Inoue T, 
Nakano T, Mizunuma H (2015) MOVEST Study Group. Clinical efficacy and safety of 
monthly oral ibandronate 100 mg versus monthly intravenous ibandronate 1 mg in 
Japanese patients with primary osteoporosis. Osteoporos Int 26:2685-2693  
28. Ramírez L, López-Pintor RM, Casañas E, Arriba L, Hernández G (2015) New non-
bisphosphonate drugs that produce osteonecrosis of the jaws. Oral Health Prev Dent 
13:385-393  
29. Allen MR (2015) Medication-Related Osteonecrosis of the Jaw: Basic and Translational 
Science Updates. Oral Maxillofac Surg Clin North Am 27:497-508  
30. Aghaloo TL, Cheong S, Bezouglaia O, Kostenuik P, Atti E, Dry SM, Pirih FQ, Tetradis  S 
(2014) RANKL inhibitors induce osteonecrosis of the jaw in mice with periapical disease. 
J Bone Miner Res 29:843-854  
31. de Molon RS, Shimamoto H, Bezouglaia O, Pirih FQ, Dry SM, Kostenuik P, Boyce           RW, 
Dwyer D, Aghaloo TL, Tetradis S (2015) OPG-Fc but not zoledronic acid discontinuation 
reverses osteonecrosis of the jaws (ONJ) in mice. J Bone Miner Res 30:1627-1640  
32. Taguchi A, Shiraki M, Tsukiyama M, Miyazaki T, Soen S, Ohta H, Nakamura T, Orimo H 
(2015) Impact of osteonecrosis of the jaw on osteoporosis treatment in Japan: Results of 
a questionnaire-based survey by the adequate treatment of osteoporosis (A-TOP) 
─ 30 ─  
research group. Calcif Tissue Int 97:542-550  
33. Taguchi A, Shiraki M, Sugimoto M, Ohta H, Soen S (2016) Lack of cooperation between 
physicians and dentists during osteoporosis treatment may increase fractures and 
osteonecrosis of the jaw. Curr Med Res Opin 32:1261-1268  
34. Curtis JR, Westfall AO, Cheng H, Deizell E, Saag KG (2008) Risk of hip fracture after 
bisphosphonate discontinuation: implications for a drug holiday. Osteoporos Int 19:1613-
1620  
35. Black DM, Rosen CJ (2016) Postmenopausal osteoporosis. N Engl J Med 374:254-262  
36. Chiu WY, Chien JY, Yang WS, Juang JM, Lee JJ, Tsai KS (2014) The risk of osteonecrosis 
of the jaws in Taiwanese osteoporotic patients treated with oral alendronate or raloxifene. 
J Clin Endocrinol Metab 99:2729-2735  
37. Barasch A, Cunha-Cruz J, Curro FA, Hujoel P, Sung AH, Vena D, Voinea-Griffin AE; 
CONDOR Collaborative Group, Beadnell S, Craig RG, DeRouen T, Desaranayake A, 
Gilbert A, Gilbert GH, Goldberg K, Hauley R, Hashimoto M, Holmes J, Latzke B, Leroux 
B, Lindblad A, Richman J, Safford M, Ship J, Thompson VP, Williams OD, Yin W (2011) 
Risk factors for osteonecrosis of the jaws: a case-control study from the CONDOR dental 
PBRN. J Dent Res 90:439-444  
38. Kim KM, Rhee Y, Kwon YD, Kwon TG, Lee JK, Kim DY (2015) Medication related 
osteonecrosis of the jaw: 2015 Position statement of the Korean Society for Bone and 
Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons. J Bone 
Metab 22:151-165  
39. Sugimoto T, Matsumoto T, Hosoi T, Miki T, Gorai I, Yoshikawa H, Tanaka Y, Tanaka S,  
Fukunaga M, Sone T, Nakano T, Ito M, Matsui S, Yoneda T, Takami H, Watanabe K, 
Osakabe T, Shiraki M, Nakamura T (2015) Three years of denosumab treatment in 
Japanese postmenopausal women and men with osteoporosis: Results from a 1-year 
open-label extension of the denosumab fracture intervention randomized placebo 
controlled trial (DIRECT). Osteoporosis Int 26:765-774  
40. Matsumoto A, Sasaki M, Schmelzeisen R, Oyama Y, Mori Y, Voss PJ. Primary wound 
─ 31 ─  
closure after tooth extraction for prevention of medication-related osteonecrosis of the jaw 
in patients under denosumab. Clin Oral Invest PMID: 26924135. DOI: 10.1007/s00784-
016-1762-y 
41. Ohga N, Yamazaki Y, Tsuboi K, Kitagawa Y (2015) Healing of osteonecrosis of the jaw 
(ONJ) after discontinuation of denosumab in a patient with bone metastases of colorectal 
cancer: a case report and hypothesis. Quintessence Int 46:621-626  
42. Guidelines on the prevention and treatment of osteoporosis 2015. The Committee for 
Development of the Guidelines on the Prevention and Treatment of Osteoporosis. Japan 
Osteoporosis Society. (In Japanese) 
43. Chahine C, Cheung MS, Head TW, Schwartz S, Glorieux FH, Rauch F (2008) Tooth 
extraction socket healing in pediatric patients treated with intravenous pamidronate. J 
Pediatr 153:719-720  
44. Maines E, Monti E, Doro F, Morandi G, Cavarzere P, Antoniazzi F (2012) Children and 
adolescents treated with neridronate for osteogenesis imperfecta show no evidence of 
any osteonecrosis of the jaw. J Bone Miner Metab 30:434-438  
45. Hoyer-Kuhn H, Semler O, Schoenau E (2014) Effect of denosumab on the growing 
skeleton in osteogenesis imperfecta. J Clin Endocrinol Metab 99:3954-3955  
46. Carlson ER (2014) Management of antiresorptive osteonecrosis of the jaws with primary 
surgical resection. J Oral Maxillofac Surg 72:655-657  
47. Bodem JP, Kargus S, Engel M, Hoffmann J, Freudlsperger C (2015) Value of nonsurgical 
therapeutic management of stage I bisphosphonate-related osteonecrosis of the jaw. J 
Craniomaxillofac Surg 43:1139-1143  
48. Bodem JP, Schaal C, Kargus S, Saure D, Mertens C, Engel M, Hoffmann J, Freudlsperger 
C (2016) Surgical management of bisphosphonate-related osteonecrosis of the jaw 
stages II and III. Oral Surg Oral Med Oral Pathol Oral Radiol 121:367-372  
49. Ikeda T, Kuraguchi J, Kogashiwa Y, Yokoi H, Satomi T, Kohno N (2015) Successful 
treatment of bisphosphonate-related osteonecrosis of the jaw (BRONJ) patients with 
sitafloxacin: new strategies for the treatment of BRONJ. Bone 73:217-222  
─ 32 ─  
50. Chan HL, McCauley LK (2013) Parathyroid hormone applications in the craniofacial 
skeleton. J Dent Res 92:18-25  
51. Ohbayashi Y, Miyake M, Sawai F, Minami Y, Iwasaki A, Matsui Y (2013) Adjunct 
teriparatide therapy with monitoring of bone turnover markers and bone scintigraphy for 
bisphosphonate-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral 
Radiol 115:e31-e37  
52. Kakehashi H, Ando T, Minamizato T, Nakatani Y, Kawasaki T, Ikeda H, Kuroshima S, 
Kawakami A, Asahina I (2015) Administration of teriparatide improves the symptoms of 
advanced bisphosphonate-related osteonecrosis of the jaw: preliminary findings. Int J Oral 
Maxillofac Surg 44:1558-1564  
53. Hinson AM, Siegel ER, Stack BC Jr (2015) Temporal correlation between bisphosphonate 
termination and symptom resolution in osteonecrosis of the jaw: a pooled case report 
analysis. J Oral Maxillofac Surg 73:53-62 
54. Thorsteinsson AL, Vestergaard P, Eiken P (2014) External auditory canal and middle ear 
cholesteatoma and osteonecrosis in bisphosphonate-treated osteoporosis patients: a 
Danish national register-based cohort study and literature review. Osteoporos Int 25:1937-
1944 
55. Akintoye SO, Hersh EV (2016) Impact of communication between physicians and dentists 
on the incidence of jaw osteonecrosis caused by bone anti-resorptives. Curr Med Res 
Opin 18:1-2  
  
─ 33 ─  
Legends to Figures 
 
Figure 1: Macroscopic pictures and panorama radiographic images of ARONJ 
A: Stage 0: a 62-year-old female. Alendronate was administered for osteoporosis. No teeth 
were removed, and there was neither bone exposure in the oral cavity, pus discharge nor pain. 
The patient complained numbness in the right mental region. 
 
B: Stage 1: a 73-year-old breast cancer patient. Denosumab was administered for bone 
metastases. The right mandibular premolar was extracted without discontinuation of 
denosumab, resulting in delayed healing. There was bone exposure around tooth extraction 
socket (arrow), but were no pus discharge and no pain. 
 
C: Stage 2: a 78-year-old male. Ibandronate was administered for osteoporosis. No teeth were 
removed. There were pain in the right maxillary molar and buccal alveolar bone exposure 
(arrow, mirror image) associated with right maxillary sinusitis (asterisk). 
 
D: Stage 3: a 68-year-old breast cancer patient. Zoledronic acid and denosumab were 
administered for bone metastases. No teeth were removed. There were buccal alveolar bone 
exposure in the maxillary and mandibular molar (arrow) and fistula formation in the 
submandibular skin. Panoramic image showed mixing of osteosclerosis and osteolysis around 
left mandibular molar (asterisk), and associated left maxillary sinusitis (arrowhead).  
Provided by Dr. Shibahara.  
 
Figure 2: Histopathologic picture of BRONJ in a breast cancer patient treated with BP.  
A: Multinucleated large osteoclasts detaching from the bone surfaces.  
B: Necrotic bones showing mosaic pattern lines of bone remodeling and bacterial aggregates 
attached to necrotic bones (Insert: massive Actinomyces growing in ARONJ lesions).  
Provided by Dr. Toyosawa. 
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Stage 0* Clinical symptoms: no bone exposure/necrosis, deep periodontal pocket, loose tooth, oral 
mucosal ulcer, swelling, abscess formation, trismus, hypoesthesia/numbness of the lower 
lip (Vincent’s symptom), non-odontogenic pain
Imaging findings: Sclerotic alveolar bone, thickening and sclerosis of lamina dura, 
remaining tooth extraction socket
Stage 1 Clinical symptoms: asymptomatic bone exposure/necrosis without sign of infection, or 
fistula in which the bone is palpable with a probe
Imaging findings: Sclerotic alveolar bone, thickening and sclerosis of lamina dura, 
remaining tooth extraction socket
Stage 2 Clinical symptoms: bone exposure/necrosis with infection, or fistula in which the bone is 
palpable with a probe. Pain in the bone-exposed site associated with redness with/without 
pus discharge
Imaging findings: image mixing diffuse osteosclerosis and osteolysis from the alveolar bone 
to jaw bone, thickening of the mandibular canal, periosteal response, maxillary sinusitis, and 
sequestration
Stage 3 Clinical symptoms: bone exposure/necrosis associated with pain, infection or at least one of 
the following symptoms, or fistula in which bone is palpable with a probe. Bone 
exposure/necrosis over the alveolar bone (e.g. reaching the mandibular inferior edge or 
mandibular ramus, or reaching the maxillary sinus or mandibular ramus or the cheek bone). 
As a result, pathologic fracture or extraoral fistula, nasal/maxillary sinus fistula formation, or 
advanced osteolysis extending to the mandibular inferior edge or maxillary sinus.
Imaging findings: osteosclerosis/osteolysis to the surrounding bone (cheek bone, palatine 
bone), pathologic mandibular fracture, and osteolysis extending to the maxillary sinus floor
Table 1 Stage of ARONJ: Clinical symptoms and imaging findings
Note: Care should be taken to avoid overdiagnosis because half of Stage 0 ARONJ cases do not progress 
to ONJ [14].
1. Local
・Invasive dental treatments including bone (e.g. tooth extraction, dental implants, apical/periodontal surgery)
・Ill-fitting denture and excessive bite force
・Poor sanitation in the oral cavity, periodontal disease and gingival abscess inflammatory disease, including apical periodontitis
・Common site: mandible> maxilla, mandibular torus, palatal torus, and mylohyoid line torus
・Root canal and orthodontic treatments are not considered to be risk factors.
2. Anti-resorptive agents
・Nitrogen-containing bisphosphonates (BPs) > Non nitrogen-containing bisphosphonates (BPs)
Nitrogen-containing BPs: zoledronate (Zometa), alendronate (Teiroc, Fosamac, Bonalon), risedronate sodium (Actonel, Benet), 
pamidronate (Aredia), incadronate (Bisphonal), minodronate (Bonoteo, Recalbon), ibandronate (Bonviva)
Non nitrogen-containing BPs: etidronate (Didronel)
・Denosumab (Ranmark, malignant tumor) (Pralia, osteoporosis)
・Drugs for malignant tumor > Drugs for osteoporosis
Drugs for malignant tumor: (Zometa, Aredia, Teiroc, Ranmark)
Drugs for osteoporosis (Didronel, Fosamac, Bonalon, Actonel, Benet, Bonoteo, Recalbon, Bonviva and Pralia)
・Dose and administration period
(Trade names are given in parentheses. For generic drugs, refer individual agent)
3. Systemic
・Cancer (breast, prostate, lung, renal and colon cancer, multiple myeloma, and other cancers)
・Diabetes, rheumatoid arthritis, hypocalcemia, hypoparathyroidism, osteomalacia, vitamin D deficiency, renal dialysis, anemia, and 
Paget's disease of bone
4. Congenital
・SNPs in MMP-2 and cytochrome P450-2C genes
5. Lifestyle
・Smoking, drinking and obesity
6. Co-administered agents
・Anticancer agents, corticosteroids and erythropoietin
・Angiogenic inhibitors (e.g. thalidomide, sunitinib, bevacizumab, and lenalidomide)
・Tyrosine kinase inhibitors
Table 2. Risk factors for ARONJ
Note: These factors are proposed to be risk factors for ARONJ but no evidence is demonstrated.   
Stage 0 and 
Stage 1
Use of anti-microbial mouthwash, rinsing and cleaning of fistula and periodontal 
pocket, and topical application or injection of local anti-microbial agents
Stage 2 Combination of anti-microbial mouthwash and agents; intractable case: combination of 
multiple anti-microbial agents, long-term anti-microbial administration, continuous 
administration of intravenous anti-microbial agents, removal of sequestra, curettage of 
necrotic bones and osteotomy 
Stage 3 Removal of sequestra, curettage of necrotic bones, osteotomy, extraction of tooth in 
exposed bone/necrotic bone as source of infection, maintenance of nutrition with 
supplements and infusions, and marginal or segmental resection of expanding necrotic 
bones 
Table 3. Treatment of ARONJ
Note: Isolated sequestra are removed without exposing bones outside lesions, regardless of disease 
stage. A tooth with symptoms in exposed necrotic bones is extracted, extraction itself unlikely 
exacerbates the necrosis.
